Insider Selling: Twist Bioscience Co. (NASDAQ:TWST) SVP Sells 1,259 Shares of Stock

Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) SVP Paula Green sold 1,259 shares of the business's stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $49.35, for a total transaction of $62,131.65. Following the completion of the sale, the senior vice president now owns 132,014 shares of the company's stock, valued at approximately $6,514,890.90. The trade was a 0.94 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Paula Green also recently made the following trade(s):

• On Friday, January 3rd, Paula Green sold 160 shares of Twist Bioscience stock. The stock was sold at an average price of $45.59, for a total value of $7,294.40.
• On Friday, December 20th, Paula Green sold 282 shares of Twist Bioscience stock. The shares were sold at an average price of $44.90, for a total value of $12,661.80.
• On Friday, December 6th, Paula Green sold 860 shares of Twist Bioscience stock. The stock was sold at an average price of $52.70, for a total value of $45,322.00.
• On Monday, November 11th, Paula Green sold 1,347 shares of Twist Bioscience stock. The stock was sold at an average price of $48.00, for a total transaction of $64,656.00.

Twist Bioscience Stock Down 2.6 %

TWST stock traded down $1.40 on Friday, reaching $52.30. 883,044 shares of the company traded hands, compared to its average volume of 786,851. The firm has a fifty day simple moving average of $48.91 and a 200-day simple moving average of $46.13. The company has a market cap of $3.12 billion, a P/E ratio of -15.47 and a beta of 1.87. Twist Bioscience Co. has a one year low of $27.41 and a one year high of $60.90. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.54.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.09. The firm had revenue of $88.70 million during the quarter, compared to the consensus estimate of $86.96 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The company's revenue was up 24.1% on a year-over-year basis. During the same period last year, the company earned ($0.75) earnings per share. Research analysts anticipate that Twist Bioscience Co. will post -2.12 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. AQR Capital Management LLC increased its position in shares of Twist Bioscience by 83.9% during the second quarter. AQR Capital Management LLC now owns 61,428 shares of the company's stock valued at $3,027,000 after acquiring an additional 28,027 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of Twist Bioscience by 3.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 31,064 shares of the company's stock worth $1,531,000 after purchasing an additional 1,104 shares in the last quarter. SG Americas Securities LLC raised its stake in shares of Twist Bioscience by 407.1% in the third quarter. SG Americas Securities LLC now owns 10,958 shares of the company's stock worth $495,000 after purchasing an additional 8,797 shares during the last quarter. CWM LLC lifted its holdings in shares of Twist Bioscience by 141.9% during the third quarter. CWM LLC now owns 5,894 shares of the company's stock valued at $266,000 after purchasing an additional 3,457 shares in the last quarter. Finally, Exchange Traded Concepts LLC boosted its position in shares of Twist Bioscience by 30.1% during the third quarter. Exchange Traded Concepts LLC now owns 20,141 shares of the company's stock valued at $910,000 after buying an additional 4,661 shares during the last quarter.

Analyst Ratings Changes

Several equities research analysts have weighed in on the stock. TD Cowen reissued a "buy" rating and set a $58.00 price target on shares of Twist Bioscience in a research report on Tuesday, November 26th. Barclays dropped their price objective on Twist Bioscience from $55.00 to $52.00 and set an "overweight" rating for the company in a report on Tuesday, November 19th. Wolfe Research assumed coverage on shares of Twist Bioscience in a research note on Friday, December 13th. They set an "outperform" rating and a $60.00 target price on the stock. Scotiabank upped their target price on Twist Bioscience from $54.00 to $62.00 and gave the stock a "sector outperform" rating in a report on Tuesday, February 4th. Finally, JPMorgan Chase & Co. raised their target price on Twist Bioscience from $35.00 to $40.00 and gave the company an "underweight" rating in a research note on Tuesday, February 4th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $53.80.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.